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Background: This research focuses on pharmaceutical competition in South Africa where
concurrent pricing legislation is being implemented without monitoring the consequences
on generic drug competition and usage.
Objective: To examine the relationship between originator drug prices and the number of
generic brands within the cardiovascular class of drugs and to compare South African
prices with international reference prices.
Method: Data on private sector drug prices was sourced from the South African Medicine Price
Registry. The relationship between themedian proportional price and the number of brands
in the therapeutic class was analysed using correlation analysis. International reference
prices were obtained from theManagement Sciences for Health International Drug Price Indicator
Guide (2012 edition).
Results: A weak correlation between originator and generic drug prices and the number of
available brands was observed, the exception being diuretic drugs. The median prices per
strength of the originator generic were still higher than the most expensive generic version
manufactured by any other company, the exception being telmisartan. Comparison of
price ratios between the originator drug, lowest priced generic and international reference
price values revealed that the originator drug prices had a median price ratio of 20.99
(interquartile range 7.31e53.46) and the lowest priced generics had a median price ratio of
4.28 (interquartile range 2.10e8.47).
Conclusion: Increased generic competition is not a predictor of lower drug prices. The study
also concludes that the current South African pharmaceutical policies have not yet ach-
ieved the lowest prices for drugs when compared internationally.
© 2015 The Authors. Publishing services by Elsevier B.V. on behalf of Johannesburg Uni-
versity. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).80; fax: þ27 31 2607792.
. Bangalee), sulemanf@ukzn.ac.za (F. Suleman).
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Access to therapeutic drugs forms an integral part of any
successful healthcare system (Bangalee, 2015). The high cost
of therapeutic drugs, which has often been cited as a barrier to
accessibility to essential medicines, has led to the promotion
of generic drug consumption in South Africa.
The restructuring of the South African public health sector
post-1994 led to the development and implementation of the
National Drug Policy (NDP) in 1996. The economic objective of
the NDP was to decrease the cost of therapeutic drugs in both
the private and public sectors (Department of Health, 1996). In
May 1997, The Medicines and Related Substances Control
Amendment Act 90 (hereinafter referred to as “the Act”) was
tabled at parliament (Deroukakis, 2007). It was implemented
to allow government to undertake a variety of actions in order
to reduce drug prices and improve the affordability of medi-
cines in line with the economic objectives of the NDP. The Act,
implemented on 2May 2003, mandates pharmacists to inform
all private patients buying prescribed medicines about the
benefits of generic alternatives (Deroukakis, 2007).
In addition to the mandatory offering of generic substitu-
tion, the 1997 amendments to the South African Medicines
and Related Substances Act, in terms of section 18A, banned
“bonusing” (preventing pharmaceutical manufacturers from
offering discounts and/or rebates to patients or healthcare
providers) and with section 22G this led to the formation of a
“pricing committee” which was tasked with constructing
“transparent pricingmechanisms” (Nicolosi&Gray, 2009). The
high levels of discounting and payment of incentives within
the pharmaceuticals supply chain had raised serious concerns
in the Department of Health (DOH) as these practices did not
pass the savings on to the consumer. Retail pharmacies and
dispensing doctors on the other hand were able to capitalise
on these incentives while consumers continued to pay the
official manufacturers' ‟listed” price (Hawkins, 2011). This also
countered the effect of generic substitution as evidence
revealed that inmany cases doctors and pharmacists were not
always agreeable to substituting the lower priced generic but
would rather dispense the more profitable product (Hawkins,
2011). This lack of transparency in prices in the supply chain
as well as the loss of benefits to consumers led to the prices of
pharmaceutical drugs being regulated by the single exit price
(SEP) legislation in 2004. This meant that drug manufacturers
could only sell their products at one price to all their cus-
tomers, regardless of the nature of the customer's order size
and consumption levels (Republic of South Africa, 1997). The
implementation of SEP in the private sector resulted in a sig-
nificant shift from a free market to a regulated one in order to
ensure transparent pricing practices for the industry. How-
ever, there is very little research on whether the imple-
mentation of this pricing policy has impacted on the use of
generic drugs, and this study attempted to look into this area
by selecting a particular group of drugs to investigate.
Globally, cardiovascular diseases (CVD) are responsible for
30% of all deaths, with the greater majority (80%) of these
deaths occurring in developing countries (van Mourik,
Cameron, Ewen, & Laing, 2010). Although HIV/AIDS remains
the leading overall cause of mortality in sub-Saharan Africa,cardiovascular disease is the second leading killer and is first
among individuals over the age of 45 years (Lopez, Mathers,
Ezzati, Jamison, & Murray, 2006). Thus, “in South Africa
approximately 195 people die per day due to CVD, represent-
ing about 20% of the daily deaths due to HIV/AIDS” (Steyn,
2007). There is currently minimal information on the cost of
CVD treatment in South Africa; however, the use of generic
drugs could potentially address the need to reduce treatment
costs. Furthermore, the growth of the South African generic
pharmaceutical market is set to rapidly accelerate owing to
the expiry of a number of patents especially in the cardio-
vascular category (Moorad, 2012). While previous studies
revealed the price-lowering effect of generic competition with
respect to the number of sellers in the overall market (Cook,
1998; Fatokun, Ibrahim, & Hassali, 2011), very little data is
available on this concept within a specific drug therapeutic
class, let alone in South Africa, which has the additional policy
of the SEP.
1.1. Aims of the study
The aim of this study was to examine the relationship be-
tween originator drug pricing and the number of available
generic brands within the cardiovascular drug class in the
context of SEP legislation, and to compare South African drug
prices with international drug prices.2. Research method and design
The quantitative study design was a secondary data analysis
based on data collected on the five classes of cardiovascular
drugs listed in the abridged South African Hypertension Guide-
lines of 2011 (Seedat & Rayner, 2012). These classes were ACE-
inhibitors, beta blockers, calcium channel blockers, diuretics
and angiotensin II antagonists. All drugs listed under each
class were categorised according to their classification in the
South African Medicines Formulary, 10th edition (Division of
Clinical Pharmacology, 2012).
Data on South African private sector prices of originator
and generic drugs was sourced from the South African Medi-
cine Price Registry which is the official website that commu-
nicates drug prices as approved by the Pharmaceutical
Economic Evaluation Unit of the Department of Health (South
African Medicine Price Registry). The number of registered
brands as at 10 June 2013 for each drug preparation was ob-
tained from the registry. Drugs chosen under eachmedication
were only included if there was a generic drug and originator
price available. Combination preparations were excluded as
they tend to alter the classification of the drug.
Originator pharmaceutical products were those initially
registered by the innovator research-based pharmaceutical
manufacturer on the basis of the documentation of their ef-
ficacy, safety and quality, whereas generic drugs were those
usually intended to be interchangeable with the originator
brand product, of the same strength and dosage form, regis-
tered after patent expiry or as licensed by the patent holder.
Originator generic drugs were defined as generic drugs that
were manufactured by the company that also manufactured
the originator drug. Due to the differences in pack sizes
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value-added tax per standard unit (i.e. price per tablet or
capsule), was computed.
The price differential between originator and generic drugs
was calculated as the difference between the price per stan-
dard unit of the originator drug and the median price per
standard unit of available generic drugs expressed as a per-
centage of the price per standard unit of the originator drug.
The relationship between the median proportional price (in
percentage) and the number of brandswas analysed bymeans
of a correlation analysis. It was hypothesised that the price
differential would be larger when the number of generic drugs
on the market increased.
Reference prices were obtained from the Management Sci-
ences for Health (MSH) International Drug Price Indicator Guide
(2012 edition) (Frye, 2013). These constitute internationally
recognised prices, based on current catalogues and price lists
obtained from pharmaceutical suppliers, international
development organisations, and government agencies. Price
comparisons were made only for the originator drugs and the
lowest price generic drugs where the median buyer interna-
tional reference price (IRP) values were available. Price sum-
maries were expressed as ratios relative to a standard set of
reference prices. The ratio indicates howmany times more or
less the comparator drug is than the IRP. For international
price comparisons, the exchange rate usedwas that of the first
day of data collection fromGoogle Finance (1 ZAR¼ 0.1017US$
on 30 July 2013). All data was analysed using Microsoft Excel
version 2010.3. Results
The findings relate to prices of the different available
strengths of 23 originator medicines and their generic equiv-
alents. Table 1 reflects the private sector prices of originator
and generic drugs sourced from the South African Medicine
Price Registry on the 10th June 2013.
As indicated in Table 1, the largest therapeutic class are the
angiotensin-converting enzyme (ACE) inhibitors with six drug
products, followed by beta blockers and angiotensin-receptor
blockers (ARB) with five and four drug products respectively.
The total number of brands for the different strengths of the
23 drug products is 346, of which 120 are ACE inhibitors, 74
beta blockers, 61 calcium channel blockers (CCBs), 50 ARBs, 30
diuretics and 11 CCBs (non-dihydropyridine). Older generics
drugs (e.g. captopril) that have been off-patent several years
back have more registered brands than newer off-patent
drugs (e.g. telmisartan).
Table 1 reveals considerable variability in the number of
drugs under each class as well as in the number of registered
brands for each drug preparation. A cursory look at Table 1
also reveals that drug products with higher number of regis-
tered brands generally have higher median cost differentials
between originator and generic versions compared to drug
preparations with lower number of registered brands.
Competition theory (effect of the number of generic equiva-
lents) was tested statistically between the price of the origi-
nator drug and generic drugs, between generic drugs, and
finally between the originator drug and the generic version ofthe drug manufactured by the originator firm. It was hypoth-
esised that increased generic entry would result in price
competition and a reduction in drug prices suggesting that the
calculated price differential would be larger as the number of
generic drugs on the market increased. Of the 346 branded
drugs, the median cost differential was 50.4% (interquartile
range 40.1%e56.98%). Of all the generic drugs identified, 75%
were more than 40% cheaper than the branded version.
Of the 23 cardiovascular drugs, four originator companies
manufactured a generic version of the drug. Table 2 shows the
cost differentials between originator and generic versions
manufactured by the originator for each of the available
strengths of the drug. The median cost differential between
originator and generic versions manufactured by the origi-
nator was 32.7% (interquartile range 22.96e41.89%). A weak
correlation between the number of generics and the size of the
cost differential was apparent (correlation coefficient 0.48).
Fig. 1 represents the median prices of the different avail-
able strengths for the four originator generic drugs in com-
parison to the originator drug, and the corresponding highest
priced generic. With the exception of telmisartan for which
there were no other generic drugs available, the price of the
originator generic was still higher than the most expensive
generic version manufactured by any other company. There
was no price difference between the originator and the origi-
nator generic version for bisoprolol.
Table 3 presents the results of different classes of cardio-
vascular drugs and the correlation coefficient for median cost
differentials between originator and generic drugs as well as
the correlation coefficient for median cost differentials be-
tween generic drugs for each drug class. The negative value
indicates an inverse relationship which shows that even
within the different classes of cardiovascular drugs, an in-
crease in the number of available brands does not result in a
reduction in drug prices. With the exception of diuretics, the
remaining drug classes display a weak correlation between
the number of generics and the size of the cost differential.
Reference pricing allows for comparisons to be drawn be-
tween South Africa and international countries. Table 4 in-
dicates that in South Africa there are large variations between
originator and generic prices and, secondly, that the lowest
prices for medications are not always being attained.
Of the 20 drugs that were compared, none of originator
drugs or lowest priced generics resulted in a ratio of one or
less. According to the MSH, it is generally accepted that pro-
curement prices for the lowest priced generics should be fairly
close to the MSH international supplier/buyer prices (that is,
ratios up to 1.00). These results indicate that the SEP policy has
not resulted in very competitive prices for drugs. The origi-
nator drug prices had a median MPR of 20.99 (interquartile
range 7.31e53.46), with atenolol having the highest median
MPR and the lowest priced generics had a median MPR of 4.28
(interquartile range 2.10e8.47), with enalapril having the
highest MPR.4. Discussion
Generic drug entry stimulates competition among the various
brands of the off-patent product available in the market and
Table 1 e Private sector prices of originator and generic drugs sourced from the South African Medicine Price Registry (10
June 2013).
Drug strength Drug class Median cost differentials
between originator
and generic drugs
Minimum SEP (R)
for each drug
Maximum SEP (R)
for each drug
Number of registered
brands for each drug
Captopril 12.5 mg ACE inhibitor 73.72 0.58 2.20 2
Captopril 25 mg ACE inhibitor 86.01 0.24 2.82 9
Enalapril 10 mg ACE inhibitor 14.63 1.02 1.55 8
Enalapril 20 mg ACE inhibitor 19.44 1.35 2.84 7
Enalapril 5 mg ACE inhibitor 17.06 0.59 1.12 7
Perindopril 10 mg ACE inhibitor 39.30 4.19 6.90 2
Perindopril 2 mg ACE inhibitor 53.69 2.82 6.09 2
Perindopril 4 mg ACE inhibitor 42.79 1.32 4.56 15
Quinapril 10 mg ACE inhibitor 56.14 1.34 4.15 3
Quinapril 20 mg ACE inhibitor 60.30 2.03 5.85 4
Quinapril 40 mg ACE inhibitor 41.91 3.65 6.28 2
Quinapril 5 mg ACE inhibitor 52.83 1.86 3.94 2
Ramipril 1.25 mg ACE inhibitor 51.07 1.96 4.78 5
Ramipril 10 mg ACE inhibitor 50.04 1.44 10.11 6
Ramipril 2.5 mg ACE inhibitor 53.57 2.73 6.36 7
Ramipril 5 mg ACE inhibitor 52.45 4.13 9.39 7
Lisinopril 10 mg ACE inhibitor 38.88 0.68 2.80 10
Lisinopril 20 mg ACE inhibitor 50.52 0.68 4.75 13
Lisinopril 5 mg ACE inhibitor 37.78 0.683 1.96 9
Nifedipine 20 mg CCB 90.89 0.63 9.20 6
Nifedipine 30 mg CCB 44.87 4.34 8.38 6
Nifedipine 60 mg CCB 41.33 6.41 11.60 5
Amlodipine 10 mg CCB 49.25 2.09 7.09 20
Amlodipine 5 mg CCB 56.80 1.18 5.05 22
Felodipine 5 mg CCB 57.49 3.65 8.58 2
Propranolol 10 mg BB 92.86 0.08 1.59 6
Propranolol 40 mg BB 95.18 0.14 3.99 7
Atenolol 100 mg BB 88.28 0.79 10.01 8
Atenolol 25 mg BB 86.98 0.48 3.70 2
Atenolol 50 mg BB 88.66 0.52 6.16 9
Acebutolol 400 mg BB 26.50 6.86 9.33 2
Bisoprolol 10 mg BB 45.21 2.53 4.91 8
Bisoprolol 5 mg BB 48.39 1.5 3.10 8
Carvedilol 1.25 mg BB 53.02 2.07 4.66 8
Carvedilol 25 mg BB 40.41 2.61 4.661 8
Carvedilol 6.25 mg BB 54.44 1.72 4.47 8
Indapamide 1.5 mg Diuretics 65.13 1.06 3.03 2
Indapamide 2.5 mg Diuretics 84.42 0.44 3.83 12
Furosemide 40 mg Diuretics (loop) 95.76 0.12 4.29 11
Spironolactone 100 mg Diuretics
(anti-aldosterone)
0.00 6.91 6.91 2
Spironolactone 25 mg Diuretics
(anti-aldosterone)
2.18 1.07 1.12 3
Losartan 100 mg ARB 8.22 2.53 3.02 11
Losartan 50 mg ARB 19.09 1.35 3.02 15
Irbesartan 150 mg ARB 51.84 1.49 8.16 4
Irbesartan 300 mg ARB 50.81 1.49 7.99 4
Valsartan 160 mg ARB 50.20 1.25 7.49 6
Valsartan 80 mg ARB 50.20 1.25 7.49 6
Telmisartan 40 mg ARB 41.89 4.84 8.33 2
Telmisartan 80 mg ARB 41.89 4.84 8.33 2
Verapamil 240 mg CCB (non-
dihydropyridine)
24.36 3.80 5.89 5
Verapamil 40 mg CCB (non-
dihydropyridine)
51.35 0.38 0.90 4
Diltiazem 240 mg CCB (non-
dihydropyridine)
21.24 7.25 9.21 2
* ACE inhibitor-angiotensin-converting enzyme inhibitor; BB e beta blocker; ARB - angiotensin receptor blocker; CCB - calcium channel blocker.
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Table 2 e Cost differentials associated with originator
and originator generics.
Drug name Number of
registered
brands identified
Cost differential
between originator
and originator
generic drugs (%)
Bisoprolol 10 mg 8 0
Bisoprolol 5 mg 8 0
Telmisartan 40 mg 2 41.89
Telmisartan 80 mg 2 41.89
Irbesartan 150 mg 4 32.81
Irbesartan 300 mg 4 31.37
Verapamil 240 mg 5 12.19
Fig. 1 e Comparison of prices for bisoprolol, telmisartan,
Irbesartan and Verapamil.
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1998). However, this phenomenon is can only take place if
there is a sufficient number of generic products in the market
(King & Kanavos, 2002). Several international studies have
sought to characterise the relationship between the number
of brands of a product and the effect on drug pricing. An
American study by Wiggins and Maness (2004) explored price
variation in anti-infective drugs and yielded different results
from previous studies conducted on several random drugs.
The study indicated that pricing variation may be sensitive to
the class of generic drugs. The analysis further showed that
increases in the number of competitors significantly reduced
prices. These findings are consistent for unregulated markets
without price caps and are consistent with findings of the
Bresnahan and Reiss study (Bresnahan & Reiss, 1991).
Fatokun et al. (2011) conducted a study in Malaysia exam-
ining the relationship between the number of multisource
drugs and their proportional prices. The results confirmed the
price-lowering effect of generic competition as shown by thedecrease in the mean proportional price as the number of
brands of the product increases. This generic price-lowering
effect was, however, not observable across all therapeutic
classes.
Adriean, De Witte, and Simoens (2008) in researching the
determinants of pricing strategies of originator and generic
drugs following patent expiry in Belgium revealed that pricing
strategies of originator and generic drugs are dependent on
the therapeutic class, with the price differential between
originator and generic drugs being higher for the cardiovas-
cular class of drugs. Pricing strategies were further influenced
by regulatory aspects such as successive reductions in refer-
ence prices and prescription status of drugs, market in-
centives in the form of price competition between generic
drugs, competition between originator and generic drugs, and
the market power of the manufacturer of the originator drug.
The results from our analysis did not indicate that there
was a price-lowering effect with increased generic competi-
tion. When testing the competition hypothesis between orig-
inator drugs and generic drugs and between generic drugs
themselves, the correlation was found to be very weak in both
instances, with the exception of diuretics.
A wide variation between the price of the least expensive
brands and the most expensive brands was observed. One
explanation for this observation is that the originator com-
panies do not engage in price competitionwith generic brands
(Kanavos & Vandoros, 2011). This is supported by the second
finding. When the price of the generic drug manufactured by
an originator company was compared to the median generic
drug price, these drugs were found to be consistently higher,
suggesting that originator companiesmay set the price ceiling
for other generic products.
The only published pricing study for South Africa was
conducted in Gauteng. This study used the WHO and Health
Action International methodology and revealed that the ma-
jority of drug prices did not compare well with the interna-
tional reference price (Xiphu&Mpanza, 2004). This was before
SEP was implemented. Similarly, our findings revealed high
prices for drugs when compared with buyer international
prices ranging from 2.69 times greater to a staggering 115.97
times greater for originator drugs. These results indicate that
current pharmaceutical policies are not optimal in South Af-
rica even though the use of generic drugs is increasing for all
classes of drugs in this study; an increase in generic usage has
thus not led to lower drug prices.
Medicine availability and pricing studies using the same
methodology in developing and middle-income countries
have been conducted (Cameron, Ewen, Ross-Degnan, Ball, &
Laing, 2009). Traditionally these studies have focused on a
core list of drugs targeting acute and chronic conditions, as
opposed to a defined therapeutic class of drugs. A study con-
ducted by van Mourik et al. (2010), however, opted to compare
the availability, price and affordability of cardiovascular
medicines (atenolol, captopril, hydrochlorothiazide, losartan
and nifedipine) across 36 countries using WHO/HAI data. The
results of the study showed great variability with regard to
procurement prices, where some countries were very
competitive and others consistently paid high prices. In
addition, patient prices were generally substantially higher
than international references prices in some of the countries
Table 3 e Correlation coefficient results for each drug
class.
Drug class Correlation coefficient
(median cost differentials
between originator
and generic drugs)
Correlation
coefficient
(between
generic drugs)
ACE inhibitor 0.19 0.08
Calcium channel
blocker
0.12 0.04
Beta blocker 0.07 0.51
Diuretics 0.78 0.92
Angiotensin-
receptor
blocker
0.77 0.39
Calcium-channel
blockers: non-
dihydropyridine
0.28 1
h e a l t h s a g e s ondh e i d 2 1 ( 2 0 1 6 ) 6 0e6 6 65that were surveyed. An interesting finding from the study was
that chronic treatment with anti-hypertensive medicines
became unaffordable when monotherapy was insufficient.
Ideally further research should be undertaken to identify the
success behind lower prices obtained in these surveyed
countries, and to determine whether these polices could not
be implemented in South Africa to obtain similar results.4.1. Limitations of the study
The main limitation noted was the lack of information on
international prices for all drugs used in the study in order to
make informed conclusive judgements on price comparisons.
Moreover, the study reflects results fromone therapeutic class
only.Table 4 e Comparison of median price ratios (MPR) with IRP va
IRP unit price (US$)
(buyer price)
Captopril 25 mg 0.01
Enalapril 10 mg 0.01
Enalapril 20 mg 0.01
Perindopril 4 mg 0.04
Nifedipine 20 mg Sr 0.02
Amlodipine 10 mg 0.01
Amlodipine 5 mg 0.01
Propranolol 10 mg 0.05
Propranolol 40 mg 0.01
Atenolol 100 mg 0.01
Atenolol 50 mg 0.01
Carvedilol 12.5 mg 0.05
Carvedilol 25 mg 0.05
Carvedilol 6.25 mg 0.09
Furosemide 40 mg 0.01
Spironolactone 100 mg 0.09
Spironolactone 25 mg 0.03
Losartan 50 mg 0.02
Verapamil 240 mg Sr 0.12
Verapamil 40 mg 0.034
a (MPR ¼ Drug Unit Price/IRP Unit Price).4.2. Recommendations
It is recommended that a study be undertaken which exam-
ines the market trends and the effects of SEP on generic drug
competition across all therapeutic classes, with particular
emphasis on diseases that rank as high priority in South Af-
rica. Results from such a study would aid policy-makers in
selectively tailoring policies to address the current high costs
of healthcare.5. Conclusion
While the pro-generic legislation may seek to increase
accessibility to medicines and improved healthcare, the
implementation of SEP may result in unintended long-term
effects by interfering with the normal market processes.
Alternative price regulations may promote active competition
among generic drug producers thus avoiding the observed
behaviour of drug prices clumping together. Interestingly, the
study revealed that the majority of generic drugs in the
dataset were more than 40% cheaper than the branded ver-
sions, which was the proposed government price at which
generic drugswill be pegged at in SouthAfrica, which provides
some assurance of the cost-reducing impact of generic drug
substitution.
The marked differences between the high South African
medicine prices and international prices warrant the imple-
mentation of future policy evaluations as well as possible
pricing interventions such as benchmarking and reference
pricing in an effort to lower drug prices. More work is required
to identify the determinants of the price differentials between
originator and generic drugs in South Africa, particularly in
light of the newly proposed healthcare restructuring.lues.
MPRa for originator drug
unit price (US$)
MPRa for lowest price
generic unit price (US$)
25.41 2.16
28.71 18.78
38.03 18.02
11.98 3.48
62.36 4.27
55.93 16.48
47.59 11.11
3.28 0.16
52.64 1.79
99.83 7.88
115.97 9.79
9.64 4.29
8.79 4.92
4.94 1.90
65.10 1.82
8.03 8.03
3.36 3.22
16.57 7.44
5.14 3.32
2.69 1.13
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